Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Briakinumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Briakinumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Briakinumab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Briakinumab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Briakinumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Briakinumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Briakinumab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Briakinumab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Briakinumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Briakinumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Briakinumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Briakinumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Briakinumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Briakinumab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Briakinumab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Briakinumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Briakinumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Briakinumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Briakinumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Briakinumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Briakinumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Briakinumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Briakinumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Briakinumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Briakinumab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Briakinumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Briakinumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Briakinumab. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Briakinumab. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Briakinumab. |
| Cladribine | Briakinumab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Briakinumab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Briakinumab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Briakinumab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Briakinumab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Briakinumab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Briakinumab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Briakinumab. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Briakinumab. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Briakinumab. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Briakinumab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Briakinumab. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Briakinumab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Briakinumab. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Briakinumab. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Briakinumab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Briakinumab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Briakinumab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Briakinumab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Briakinumab. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Briakinumab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Briakinumab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Briakinumab. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Briakinumab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Briakinumab. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Briakinumab. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Briakinumab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Briakinumab. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Briakinumab. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Briakinumab. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Briakinumab. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Briakinumab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Briakinumab. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Briakinumab. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Briakinumab. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Briakinumab. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Briakinumab. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Briakinumab. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Briakinumab. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Briakinumab. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Briakinumab. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Briakinumab. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Briakinumab. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Briakinumab. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Briakinumab. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Briakinumab. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Briakinumab. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Briakinumab. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Briakinumab. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Briakinumab. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Briakinumab. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Briakinumab. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Briakinumab. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Briakinumab. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Briakinumab. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Briakinumab. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Briakinumab. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Briakinumab. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Briakinumab. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Briakinumab. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Briakinumab. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Briakinumab. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Briakinumab. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Briakinumab. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Briakinumab. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Briakinumab. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Briakinumab. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Briakinumab. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Briakinumab. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Briakinumab. |